MOUNJARO® 5mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 5mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 5mg/0.6ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 5mg KwikPen is a once-weekly tirzepatide injection in a pre-filled pen, supporting glycaemic control and weight management in adults with type 2 diabetes across EU and US markets. Building on the 2.5mg initiation dose, the 5mg strength offers the first titration step for patients progressing in their treatment plan. For those looking to buy MOUNJARO® 5mg KwikPen online, the Maylips support team is more than happy to provide guidance.

MOUNJARO® 5mg KwikPen contains tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and Company, indicated for adults with type 2 diabetes and — in jurisdictions where locally authorized, including the EU — for chronic weight management in eligible adults [2][3]. The 5mg strength is the first dose-escalation step following the 2.5mg initiation dose, supporting a gradual titration approach before higher maintenance strengths are considered. Eli Lilly introduced an updated KwikPen device in April 2026, revising the internal hardware across all approved strengths while leaving the tirzepatide formulation, concentration, and once-weekly dosing schedule unchanged. Licensed practitioners looking to buy MOUNJARO® 5mg KwikPen online can reach the Maylips support team for product information and ordering guidance.

Product Specifications

• Strength: 5mg per dose
• Active Ingredient: Tirzepatide
• Dosage Form: 5mg solution for injection supplied in one multidose KwikPen containing four pre-filled doses
• Manufacturer: Eli Lilly and Company
• Marketing Authorization: European Commission (EU); U.S. Food and Drug Administration (US)
• Administration: Once-weekly subcutaneous injection
• Indications: Type 2 diabetes management in adults; chronic weight management in adults where locally authorized

Regulatory status is current as of the date of publication. Healthcare professionals should verify the latest regional prescribing information before clinical use or supply.

MOUNJARO® 5mg KwikPen is a prescription medicine containing tirzepatide — the first approved dual GIP and GLP-1 receptor agonist and the active substance across all MOUNJARO® dose strengths [4]. The MOUNJARO® 5mg KwikPen solution is prescribed after completion of the 2.5mg initiation phase and is the first dose-escalation step before higher maintenance strengths are evaluated. Its simultaneous activation of two complementary incretin pathways distinguishes MOUNJARO® from therapies that engage only the GLP-1 receptor [3].

Each KwikPen contains four once-weekly doses for subcutaneous administration and is designed for single-patient use. No manual dose preparation is required between injections. In the U.S., MOUNJARO® is FDA-approved for adults with type 2 diabetes [2]. In the EU, the European Commission granted marketing authorization following EMA evaluation for both type 2 diabetes and chronic weight management indications [3]. In the U.S., tirzepatide for chronic weight management is authorized under a separate brand name.

The April 2026 KwikPen device update did not affect the medicine. Patients transitioning from earlier pen versions continue on the same prescribed dose, injection schedule, and treatment pathway, while benefiting from improved end-of-use visibility.

Practitioners who plan to buy weight-loss medicine can reach out to the Maylips support team, which can walk them through the full weight-management category.

In April 2026, Eli Lilly introduced a redesigned KwikPen device across all MOUNJARO® strengths in markets where the multi-dose pen format is available. The update applies only to the delivery device. The tirzepatide formulation, concentration, approved indications, and recommended once-weekly dosing schedule are unchanged.

The redesign addresses two practical limitations of earlier pen versions:

• Extended internal plunger: A new internal component added behind the plunger increases its overall length, making it easier to confirm that each weekly dose has been fully delivered.
• End-of-use indicator: After the fourth and final injection, the plunger advances close to the tip of the pen, providing a clear visual signal that the device is depleted and ready for disposal.
• Golden dose elimination: The redesigned mechanism removes the residual liquid that some patients were extracting as an unofficial fifth dose from older pen models, a practice sometimes referred to as the “golden dose.”

Practitioners should orient patients who are switching from earlier MOUNJARO® devices to the updated pen’s appearance and end-of-use indicators before dispensing. The clinical profile of the product — including its efficacy, pharmacokinetics, and safety — is not affected by the hardware changes.

Tirzepatide is a synthetic peptide with dual agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, each engaged by independent binding domains on a single molecule [2]. This dual receptor mechanism is the defining pharmacological characteristic of tirzepatide and sets it apart from single-pathway GLP-1 receptor agonists [4].

GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, collectively reducing postprandial glucose excursions [2]. GIP receptor activation supports insulin responsiveness, modulates adipose lipid metabolism, and may reduce the gastrointestinal burden associated with isolated GLP-1 receptor stimulation [2].

In the SURPASS clinical program, tirzepatide produced greater reductions in HbA1c and body weight than placebo, with head-to-head data from the SURPASS-2 trial showing superior glycemic and weight outcomes compared with injectable semaglutide [1]. Because insulin release under tirzepatide remains glucose-dependent, the risk of hypoglycemia when used as monotherapy is generally low [2]. The 5mg dose allows patients to adapt to the incretin-based mechanism before progressing to higher strengths every four weeks as clinically appropriate.

MOUNJARO® 5mg KwikPen is indicated as an adjunct to diet and exercise for glycemic improvement in adults with type 2 diabetes [2]. In the EU, marketing authorization also covers chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related comorbidity [3]. In the U.S., tirzepatide for chronic weight management is approved under a separate brand name; MOUNJARO® in the U.S. carries the type 2 diabetes indication only [2].

Clinical considerations before initiating or escalating to the 5mg dose include:

• Dose progression: Patients should complete at least four weeks on the 2.5mg initiation dose before advancing to 5mg [2].
• Pre-treatment assessment: Evaluate renal function, cardiovascular risk, diabetic retinopathy status, and gastrointestinal tolerability before escalation.
• Ongoing monitoring: Track glycemic response and body weight throughout treatment; adjust doses of co-prescribed secretagogues as clinically indicated [2].
• Exclusions: MOUNJARO® is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis, and should not be co-administered with other GLP-1 receptor agonists.

All prescribing should follow the most current regional product information applicable to the practitioner’s jurisdiction.

MOUNJARO® 5mg is administered once weekly by subcutaneous injection. Approved sites include the abdomen, thigh, and outer upper arm; injection sites should be rotated at each administration to reduce localized reactions. Each KwikPen delivers a fixed 5mg solution for injection per activation — no manual dose preparation is needed between uses [2].

Practitioners who plan to buy MOUNJARO® product pages or want to check wholesale options should contact the Maylips support team to confirm availability and ordering requirements for their practice.

Key administration guidance for patients includes:

• Pre-injection inspection: The 5mg solution for injection should appear clear and colorless, free from visible particles or discoloration, before each use.
• Injection technique: Press the activation button firmly and hold the pen against the skin for approximately 10 seconds to ensure the full dose is delivered [2].
• Oral medication timing: Tirzepatide delays gastric emptying and may affect absorption of certain oral medicines with narrow therapeutic windows; dose timing adjustments may be warranted [2].
• Missed dose management: A missed dose may be administered within four days of the scheduled date. If more than four days have passed, skip that dose and resume the regular weekly schedule; do not administer an additional injection to compensate [2].

The KwikPen is for single-patient use only. Discard the device after the fourth dose is confirmed, using the updated plunger position as a disposal indicator where the April 2026 redesign applies.

Adverse reactions with MOUNJARO® 5mg are predominantly gastrointestinal and are most pronounced during dose escalation from the 2.5mg initiation dose. Most events are mild to moderate in severity and tend to ease as patients continue therapy [2].

Frequently reported adverse reactions include nausea, vomiting, diarrhea, constipation, decreased appetite, and upper abdominal discomfort [2]. Injection site reactions — such as localized redness, swelling, or tenderness — are also reported and typically resolve without intervention [2].
Less common but clinically relevant events include pancreatitis, gallbladder disorders, and acute kidney injury related to dehydration [2]. The risk of hypoglycemia is low when tirzepatide is used as monotherapy but rises when co-administered with insulin or sulfonylureas; doses of concomitant secretagogues may require adjustment [2].

Important Safety Notice: Tirzepatide causes thyroid C-cell tumors in rodents; it is unknown whether it causes these tumors in humans. It is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [2].

Any suspected serious adverse event should be reported through the applicable local pharmacovigilance system. In the UK and EU, MOUNJARO® carries the black triangle (▼) designation, indicating it is subject to additional monitoring by regulatory authorities to capture new post-marketing safety data; practitioners in these markets should report adverse reactions through the Yellow Card Scheme (UK) or the EudraVigilance system (EU) as appropriate. Full safety data, contraindications, and drug interaction information are available in the current regional prescribing information.

MOUNJARO® 5mg KwikPen is a prescription-only medicine. Supply is restricted to licensed healthcare professionals and authorized healthcare facilities.

• United States: MOUNJARO® received initial FDA approval in 2022 for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise [2]. In the U.S., tirzepatide for chronic weight management is authorized under a separate brand name [2].
• European Union: The European Commission granted marketing authorization for MOUNJARO® (tirzepatide) following a positive opinion from the European Medicines Agency (EMA), covering both type 2 diabetes and chronic weight management indications [3]. MOUNJARO® carries the ▼ symbol in EU markets, indicating it is subject to additional monitoring.

When buying online, licensed practitioners should verify the applicable regulatory status, approved indications, and jurisdiction-specific supply conditions before placing orders. Prescribing and dispensing must follow the most current regional product information.

1. Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. 2024. https://pubmed.ncbi.nlm.nih.gov/38613667/
2. MOUNJARO (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
3. Eli Lilly and Company. Lilly Receives European Marketing Authorization for tirzepatide (Mounjaro). Eli Lilly. 2024. https://www.lilly.com/eu/story/lilly-receives-european-marketing-authorization-for-tirzepatide-mounjaro-r
4. Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for adults with type 2 diabetes. Eli Lilly. 2022. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and

All content on this website is intended for informational purposes and does not constitute medical advice.

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.